SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Gilead Sciences

116

Gilead Sciences

GILD

California-based Gilead is a biopharmaceutical firm best known for its hepatitis C cures Sovaldi and Harvoni.

Looking for leads, investment insights, or competitive intelligence?

CEO

John F. Milligan IV

CEO Title

President, Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Foster City, Calif.

Years on Fortune 500 List

10

Employees

10,000

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$26,107-14.1%
Profits ($M)$4,628.0-65.7%
Assets ($M)$70,283
Total Stockholder Equity ($M)$20,442
Market Value — as of March 29, 2018 ($M)$98,298
Profit Ratios
Profit as % of Revenues17.7%
Profits as % of Assets6.6%
Profits as % of Stockholder Equity22.6%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)3.51
EPS % Change (from 2016)-64.7%
EPS % Change (5 year annual rate)16.4%
EPS % Change (10 year annual rate)15.4%
Total Return
Total Return to Investors (2017)2.9%
Total Return to Investors (5 year, annualized)15.8%
Total Return to Investors (10 year, annualized)12.7%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

The blockbuster public offering pegs Allogene's market value at more than $2 billion.

Read More →
The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs

Celgene and Novartis are among the companies accused of thwarting generic drugs.

Read More →
Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race

On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.

Read More →
New Zealand Is About to Make the Revolutionary HIV Prevention Drug Truvada Almost Free

The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.

Read More →